Live Analyst Rating Changes 1505 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Dev Prasad
LUCI
Dev Prasad
Lucid Capital
Wall Street Analyst
★★★★★
#64
on 13Foresight · ranked by our own returns
69%
Success Rate
+80.2%
Average Return
9 of 13 calls profitable · +65.1% vs benchmark
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 69% of Dev Prasad's ratings turned a profit when each position was held for 1 year — averaging +80.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

7 Buy 1 Hold 0 Sell
Dev's Stock Coverage 14 ratings · 2026-06-18
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
QNRX
Quoin Pharmaceuticals
 May 04, 2026 BUY Strong Buy
+665.7% avg upside
7 analysts
$30.00
549.34% Upside
 -9.1%
ABOS
Acumen Pharmaceuticals
 Dec 17, 2025 BUY Strong Buy
+258.4% avg upside
10 analysts
$6.00
166.65% Upside
 +14.6%
PVLA
Palvella Therapeutics
 Dec 15, 2025 BUY Strong Buy
+46.0% avg upside
27 analysts
$212.00
88.25% Upside
 +27.1%
IFRX
InflaRx
 Nov 10, 2025 BUY Buy
+391.6% avg upside
11 analysts
$24.00
1218.63% Upside
 +50.6%
VRCA
Verrica Pharmaceuticals
 Nov 05, 2025 BUY Strong Buy
+213.5% avg upside
8 analysts
$19.00
225.93% Upside
 +90.4%
TSE:MDNA
Medicenna Therapeutics Corp
 Oct 14, 2025 BUY Strong Buy
+1129.7% avg upside
9 analysts
$4.00
863.86% Upside
 ·
ATYR
aTyr Pharma
 Sep 15, 2025 HOLD Buy
+1967.4% avg upside
17 analysts
$1.00
115.98% Upside
 -48.8%
CUE
Cue Biopharma
 Aug 25, 2025 BUY Strong Buy
-64.8% avg upside
9 analysts
$4.00
85.13% Downside
 -6.2%
IRD
Opus Genetics
 Jun 17, 2025 BUY Strong Buy
+155.2% avg upside
23 analysts
$5.00
23.21% Upside
 +325.5%
EDSA
Edesa Biotech
 May 23, 2025 BUY Strong Buy
+54.4% avg upside
6 analysts
$9.00
30.83% Upside
 +433.7%
ALGS
Aligos Therapeutics
 May 01, 2025 BUY Strong Buy
+765.6% avg upside
11 analysts
$36.00
572.84% Upside
 +0.9%
IBIO
Ibio
 Dec 17, 2024 BUY Strong Buy
+262.3% avg upside
11 analysts
$6.00
274.95% Upside
 -21.9%
CALC
CalciMedica
 Dec 17, 2024 BUY Buy
+3372.0% avg upside
9 analysts
$13.00
1447.68% Upside
 +80.6%
AVTX
Avalo Therapeutics
 Dec 17, 2024 BUY Strong Buy
+252.5% avg upside
19 analysts
$24.00
55.85% Upside
 +105.2%
🔒 9 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Dev Prasad — Frequently Asked Questions
How accurate are Dev Prasad's stock ratings?
Based on the calls 13Foresight could measure, about 69% of Dev's ratings were profitable over a one-year hold, with an average return of +80.2% per rating, or +65.1% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Dev ranked on 13Foresight?
Dev Prasad is currently ranked #64 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Dev cover?
Dev most recently has ratings on QNRX, ABOS, PVLA, IFRX, VRCA, TSE:MDNA, ATYR, CUE, IRD, EDSA, ALGS, IBIO and 2 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.